Literature Library

Standards of Medical Care in Diabetes—2006
American Diabetes Association. Diabetes Care. 2006;29(suppl1):S4-S42.

A Systematic Review of Adherence With Medications for Diabetes
Cramer JA. Diabetes Care. 2004;27:1218-1224.

No Substantial Psychological Impact of the Diagnosis of Type 2 Diabetes Following Targeted Population Screening: The Hoorn Screening Study
Adriaanse MC, Snoek FJ, Dekker JM, Spijkerman AM, Nijpels G, Twisk JW, Van Der Ploeg HM, Heine RJ. Diabet Med. 2004;21:992-998.

Critical-Evaluation of Adult Treatment Panel III Criteria in Identifying Insulin Resistance With Dyslipidemia
Liao Y, Hutto A, Kwon S, Jenkins AJ, Shaughnessy S, Klein RL, Wallace P, Garvey WT. Diabetes Care. 2004;27:978-983

Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes
Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Diabetes Care. 2004;27:2874-2880.

Inhibition of PKC β by Oral Administration of Ruboxistaurin Is Well Tolerated and Ameliorates Diabetes-induced Retinal Hemodynamic Abnormalities in Patients
Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell S-E. Invest Ophthalmol Vis Sci. 2006;47:86-92. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell S-E. Invest Ophthalmol Vis Sci. 2006;47:86-92.

Retinal Vascular Caliber and Risk of Retinopathy in Young Patients With Type 1 Diabetes
Alibrahim E, Donaghue KC, Rogers S, Hing S, Jenkins AJ, Chan A, Wong TY. Ophthalmology. 2006;113:1499-1503.

ADA Clinical Practice Guidelines
American Diabetes Association. Diabetes Care. 2005;28(suppl 1):S1-S79.

Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
Amori RE, Lau J, Pittas AG. JAMA. 2007;298:194-206

Fenofibrate Reduces Progression to Microalbuminuria Over 3 Years in a Placebo-controlled Study in Type 2 Diabetes
Ansquer J, Foucher C, Rattier S, Taskinen M, Steiner G, for the DIAS Investigators. Am J Kidney Dis. 2005;45:485-493.

Variability in Activity May Precede Diabetic Foot Ulceration
Variability in Activity May Precede Diabetic Foot Ulceration Armstrong DG, Lavery LA, Holtz-Neiderer K, Mohler MJ, Wendel CS, Nixon BP, Boulton AJ. Diabetes Care. 2004;27:1980-1984.

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes
Aschner P, Kipnes MS, Luncenford JK, Sanchez M, Mickel C, William-Herman DE; Sitagliptin Study 021 Group. Diabetes Care. 2006;29:2632-2637.

Early Events in Islets and Pancreatic Lymph Nodes in Autoimmune Diabetes
Aspord C, Rome S, Thivolet C. J Autoimmun. 2004;23:27-35.

Lower Haemoglobin Level and Subsequent Decline in Kidney Function in Type 2 Diabetic Adults Without Clinical Albuminuria
Babazano T, Hanai K, Suzuki K, et al. Diabetologia. 2006;49:1387-1393.

Angiotensin-Receptor Blockade Versus Converting-Enzyme Inhibition in Type 2 Diabetes and Nephropathy
Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group. N Engl J Med. 2004;351:1952-1961.

A New Wound-Based Severity Score for Diabetic Foot Ulcers: A Prospective Analysis of 1,000 Patients.

Beckert S, Witte M, Wicke C, Konigsrainer A, Coerper S. Diabetes Care. 2006;29:988-992.

A New Wound-Based Severity Score for Diabetic Foot Ulcers
Beckett S, Witte M, Wicke C, Konigrainer A, Coerper S. Diabetes Care. 2006;29(5):988-992.

Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients with Type 2 Diabetes Without Manifest Cardiovascular Disease
Beishuizen ED, van de Ree MA, Jukema JW, Tamsma JT, van der Vijver JC, Meinders AE, Putter H, Huisman MV. Diabetes Care. 2004;27:2887-2892.

Diabetic Retinopathy: The Latest in Current Management
Bhavsar AR. Retina.2006;26:S71-S79.

Predictors of Heart Failure Among Women With Coronary Disease
Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Hulley SB, Grady D, Shlipak MG. Circulation. 2004;110:1424-1430.

Value of Repeated Measures of Nerve Conduction and Quantitative Sensory Testing in a Diabetic Neuropathy Trial
Bird SJ, Brown MJ, Spino C, Watling S, Foyt H. Muscle & Nerve. May 2006.

Interim Analysis of the Effects of Exenatide Treatment on A1C, Weight and Cardiovascular Risk Factors over 82 weeks in 314 Overweight Patients with Type 2 Diabetes
Blonde L, Klein EJ, Zhang B, et al. Diabetes Obes Metab. 2006;8:435-447.

Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Diabetes. 2005;54:146-151.

Diabetic Neuropathies: A Statement by the American Diabetic Association
Boulton AJM, Vinik AI, Arezzo JC, et al. Diabetes Care. 2005;28:956-962.

Diabetes Mellitus and Health-Related Quality of Life Among Older Adults: Findings from the Behavioral Risk Factor Surveillance System (BRFSS)
Brown DW, Balluz LS, Giles WH, Beckles GL, Moriarty DG, Ford ES, Mokdad AH. Diabetes Res Clin Pract. 2004;65:105-115.

Laser Damage to Retinal Ganglion Cells: The Effect On Circadian Rhythms
Bughi S, Shaw S, Bessman A. J Diabetes Complications. 2006;20:184-187.

The Impact of a Decade of Changing Treatment on Rates of Severe Hypoglycemia in a Population-Based Cohort of Children with Type 1 Diabetes
Bulsara MK, Holman CD, Davis EA, Jones TW. Diabetes Care. 2004;27:2293-2298.

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-treated Patients With Type 2 Diabetes
Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Diabetes Care. 2004;27:2628-2635.

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association
Buse JB, Ginsberg HN, Bakris GL, et al. Diabetes Care. 2007;30:162-172.

Glucagon-like Peptide-1 Prevents Beta Cell Glucolipotoxicity
Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M. Diabetologia. 2004;47:806-815.

A Telemedicine Program for Diabetic Retinopathy in a Veterans Affairs Medical Center—The Joslin Vision Network Eye Health Care Model
Cavallerano AA, Cavallerano JD, Katalinc P, et al. Am J Ophthalmol. 2005;139:597-604.

Meta-Analysis: Efficacy and Safety of Inhaled Insulin Therapy in Adults With Diabetes Mellitus
Ceglia L, Lau J, Pittas AG. Ann Intern Med. 2006;145:665-675.

Postprandial Glucose Regulation and Diabetic Complications
Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J. Arch Intern Med. 2004;164:2090-2095.

Insulin Detemir: A Review of Its Use in the Management of Type 1 and 2 Diabetes Mellitus
Chapman TM, Perry CM. Drugs. 2004;64:2577-2595.

The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive)
Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A. Diabetes Care. 2004;27:1647-1653.

Long-term Efficacy and Tolerability of Add-on Pioglitazone Therapy To Failing Monotherapy Compared With Addition of Gliclazide or Metformin in Patients With Type 2 Diabetes
Charbonnel B, Schernthaner G, Brunetti P, et al. Diabetologia. 2005;48:1093-1104.

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
Charbonnel B, Karasik A, Lu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Diabetes Care. 2006;29:2638-2643.

Role of Lipid Control in Diabetic Nephropathy
Chen H-C, Guh J-Y, Chang J-M, Hsieh M-C, Shin S-J, Lai Y-H. Kidney Int. 2005;67(suppl 94):S60-S62.

Population-based Stepwise Screening for Unrecognised Type 2 Diabetes Is Ineffective in General Practice Despite Reliable Algorithms
Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K. Diabetologia. 2004;47:1566-1573.

Effects of Difference Doses of Physical Activity on Cardiorespiratory Fitness Among Sedentary, Overweight or Obese Postmenopausal Women With Elevated Blood Pressure: A Randomized Controlled Trial
Church TS, Earnest CP, Skinner JS, Blair SN. JAMA. 2007;297:2081-2091.

A Model to Estimate the Lifetime Health Outcomes of Patients With Type 2 Diabetes: The United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS No. 68)
Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM, Holman RR. Diabetologia. 2004;47:1747-1759.

Assessing the Impact of Visual Acuity on Quality of Life in Individuals With Type 2 Diabetes Using the Short Form-36
Clarke PM, Simon J, Cull CA, Holman RR. Diabetes Care. 2006;29:1506-1511.  

Primary Prevention of Cardiovascular Disease With Atorvastatin in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre Randomised Placebo-Controlled Trial
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, on behalf of the CARDS investigators. Lancet. 2004;364:685-696.

Relationships Between Hyperglycemia and Cognitive Performance Among Adults
Cox DJ, Kovatchev BP, Gonder-Frederick LA, et al. Diabetes Care. 2005;28:71-77.

The Renal Protective Effects of Angiotensin II Receptor Blockers in Type 2 Diabetes Mellitus
Coyle JD, Gardner SF, White CM. Ann Pharmacother. 2004;38:1731-1738.

Glucagon-like Peptide 1: Evolution of an Incretin into a Treatment for Diabetes
D’Alessio DA, Vahl TP. Am J Physiol Endocrinol Metab. 2004;286:E882-E890.

Endothelial Dysfunction, Inflammation and Diabetes
Dandona P, Aljada A, Chaudhuri A, Mohanty P. Rev Endocr Metab Disord. 2004;5:189-197.

Making Sense of Diabetes: Cultural Models, Gender and Individual Adjustment to Type 2 Diabetes in a Mexican Community
Daniulaityte R. Soc Sci Med. 2004;59:1899-1912.

Chronic Painful Peripheral Neuropathy in an Urban Community: a Controlled Comparison of People With and Without Diabetes
Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Diabet Med. 2004;21:976-982.

Is Self-Monitoring of Blood Glucose Appropriate for All Type 2 Diabetic Patients? The Fremantle Diabetes Study
Davis W, Bruce D, Davis T. Diabetes Care. 2006;29:1764-1770.

Intensive Diabetes Treatment and Cardiovascular Disease in Patients With Type 1 Diabetes.
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. N Engl J Med. 2005;353:2643-2653.

Intensive Insulin Therapy in the Intensive Care Unit: Assessment by Continuous Glucose Monitoring
De Block C, Manuel-Y-Keenoy B, Van Gaal L, Rogiers P. Diabetes Care. 2006;29:1750-1756.

Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia
Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia Després J-P, Golay A, Sjöstöm for the Rimonabant in Obesity–Lipids Study Group. N Engl J Med. 2005;353:2121-2134.

Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes
Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. J Clin Endocrinol Metab. 2004;89:5462-5468.

Diabetic Somatic Neuropathies
Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetes Care. 2004;27:1458-1486.

A Randomized Multicenter Trial Comparing the GlucoWatch Biographer With Standard Glucose Monitoring in Children With Type 1 Diabetes
The Diabetes Research in Children Network (DirecNet) Study Group. Diabetes Care. 2005;28:1103-1106.

Secondary Prevention of Macrovascular Events in Patients With Type 2 Diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A Randomised Controlled Trial
Dormandy JA, Charbonnel B, Eckland DJA, et al. Lancet. 2005;366:1279-1289.

A Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion with Multiple Daily Injections Using Insulin Glargine
Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. Diabetes Care. 2004;27:1554-1558.

Effect of Ramipril on the Incidence of Diabetes
The DREAM Trial Investigators. N Engl J Med. 2006;355:1-12.

Effect of Rosiglitazone on the Frequency of Diabetes in Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose: a Randomized Controlled Trial
The DREAM Trial Investigators. Lancet. 2006;368:1096-1105.

Reducing Amputation Rates in Patients With Diabetes at a Military Medical Center: The Limb Preservation Service Model
Driver VR, Madisen J, Goodman RA. Diabetes Care. 2005;28:248-253.

Prevalence and Trends of a Metabolic Syndrome Phenotype Among U.S. Adolescents, 1999–2000
Duncan GE, Li SM, Zhou XH. Diabetes Care. 2004;27:2438-2443.

Rates of Glucose Change Measured by Blood Glucose Meter and the GlucoWatch Biographer During Day, Night, and Around Mealtimes
Dunn TC, Eastman RC, Tamada JA. Diabetes Care. 2004;27:2161-2165.

The Influence of Obesity and Diabetes on the Risk of Cesarean Delivery
Ehrenberg HM, Durnwald CP, Catalano P, Mercer BM. Am J Obstet Gynecol. 2004;191:969-974.

Prevalence of Diabetes Complications in Adolescents With Type 2 Compared With Type 1 Diabetes 
Eppens MC, Craig ME, Cusumano J, et al. Diabetes Care. 2006;29:1300-1306.

New and Experimental Approaches to Treatment of Diabetic Foot Ulcers: A Comprehensive Review of Emerging Treatment Strategies
Eldor R, Raz I, Ben Yehuda A, Boulton AJ. Diabet Med. 2004;21:1161-1173.

Use of Multisystemic Therapy to Improve Regimen Adherence among Adolescents With Type 1 Diabetes in Chronic Poor Metabolic Control
Ellis DA, Frey MA, Naar-King S, Templin T, Cunningham P, Cakan N. Diabetes Care. 2005;28:1604-1610.

Prevalence of Diabetes Complications in Adolescents With Type 2 Compared With Type 1 Diabetes 
Eppens MC, Craig ME, Cusumano J, et al. Diabetes Care. 2006;29:1300-1306.

Effectiveness of Progressive Dose-Escalation of Exenatide (Exendin-4) in Reducing Dose-Limiting Side Effects in Subjects with Type 2 Diabetes
Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Diabetes Metab Res Rev. 2004;20:411-417.

Insulin Resistance is a Risk Factor for Progression to Type 1 Diabetes
Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Diabetologia. 2004;47:1661-1667.

Trends in Cardiovascular Complications of Diabetes
Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D’Agostino RB Sr, Wilson PW, Savage PJ. JAMA. 2004;292:2495-2499.

A Randomized Controlled Trial of Insulin Pump Therapy in Young Children With Type 1 Diabetes
Fox LA, Buckloh LM, Smith SD, Wysocki T, Mauras N. Diabetes Care. 2005;28:1277-1281.

A Randomized Controlled Trial of Sweet Talk, a Text-Messaging System to Support Young People With Diabetes
Franklin VL, Waller A, Pagliari C, Greene SA. Diabet Med. 2006;23:1332-1338.

Empowerment and Self-Management of Diabetes
Funnell MM, Anderson RM. Clin Diabetes. 2004;22:123-127.

Type 2 Diabetes: Treat to Target
Funnell MM, Kruger DF. Nurse Pract. 2004;29:11-15, 19-25.

The effect of improved postprandial blood glucose control on postprandial metabolism and markers of vascular risk in people with Type 2 diabetes
Gallagher A. Diabet Res Clin Pract. 2005;67:196-203.

Improved Glycemic Control Without an Increase in Severe Hypoglycemic Episodes in Intensively Treated Patients With Type 1 Diabetes Receiving Morning, Evening, or Split-Dose Insulin Glargine
Garg SK, Gottlieb PA, Hisatomi ME, D’Souza A, Walker AJ, Izuora KE, Chase HP. Diabetes Res Clin Pract. 2004;66:49-56.

Transplantation in the Diabetic Patient with Advanced Chronic Kidney Disease: A Task Force Report
Gaston RS, Basadonna G, Cosio FG, Davis CL, Kasiske BL, Larsen J, Leichtman AB, Delmonico FL. Am J Kidney Dis. 2004;44:529-542.

Preserve-β: Two-year Efficacy and Safety of Initial Combination Therapy with Nateglinide or Glyburide Plus Metformin
Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron M. Diabetes Care. 2005;28:2093-2099.

The Rationale for Paired Pre- and Postprandial Self-monitoring of Blood Glucose: The Role of Glycemic Variability in Micro- and Macrovascular Risk
Gerich JE, Odawara M, Terauchi Y. Curr Med Res Opin. 2007;23:1791-1798.

Pregnancy Outcome After First-Trimester Exposure to Metformin: a Meta-Analysis
Gilbert C, Valois M, Koren G. Fertil Steril. 2006;86:658-663.

The Rising Incidence of Childhood Type 1 Diabetes and Reduced Contribution of High-Risk HLA Haplotypes 
Gillespie KM, Bain SC, Barnett AH, Bingley PJ, Christie MR, Gill GV, Gale EAM. Lancet. 2004;364:1699-1700.

Intravitreal Triamcinolone for Refractory Diabetic Macular Edema
Two-Year Results of a Double-Masked, Placebo-Controlled, Randomized Clinical Trial
Gillies M, Sutter F, Simpson J, Larsson J, Ali H, Zhu M. Ophthalmology. 2006;113:1533-1538.

Predictors of Health Care Costs in Adults With Diabetes
Gilmer TP, O’Connor PJ, Rush WA, et al. Diabetes Care. 2005;28:59-64.

Factors Associated With Progression to Macroalbuminuria in Microalbuminuric Type 1 Diabetic Patients: The EURODIAB Prospective Complications Study
Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N. Diabetologia. 2004;47:1020-1028.

Retinal Thickness in Diabetic Retinopathy: Comparison of Optical Coherence Tomography, the Retinal Thickness Analyzer, and Fundus Photography
Goebel W, Franke R. Retina. 2006;26:49-57.

Duloxetine vs Placebo in Patients With Painful Diabetic Neuropathy
Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Pain. 2005;116:109-118.

Improving Metabolic Control in Sub-Optimally Controlled Subjects With Type 1 Diabetes: Comparison of Two Treatment Algorithms Using Insulin Glargine
Gomis R, Storms F, Conget I, Sinnassamy P, Davies M; on behalf of the AT.LANTUS Study Group. Diabetes Res Clin Pract. 2006;doi:10.1016/j.diabres.2006.10.002.

Quality of Diabetes Care in US Academic Medical Centers
Grant R, Buse J, Meigs J. Diabetes Care.2005;28:337-442.

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, for the Coordinating Committee of the National Cholesterol Education Program. Circulation. 2004;110:227-239.

Helicobacter Pylori Prevalence in Diabetic Patients and its Relationship With Dyspepsia and Autonomic Neuropathy
Gulcelik NE, Kaya E, Demirbas B, et al. J Endocrinol Invest. 2005;28:214-217.

Effects of Orlistat on Obesity-Related Diseases—a Six-Month Randomized Trial
Guy-Grand B, Drouin P, Eschwege E, Gin H, Joubert JM, Valensi P. Diabetes Obes Metab. 2004;6:375-383.

Epidemiology and Treatment of Neuropathic Pain: The UK Primary Care Perspective
Hall G, Carroll D, Parry D, McQuay H. Pain. 2006;122:156-162.

The Effect of Liraglutide, a Long-Acting Glucagon-Like Peptide 1 Derivative, on Glycemic Control, Body Composition, and 24-h Energy Expenditure in Patients With Type 2 Diabetes
Harder H, Nielsen L, Thi TD, Astrup A. Diabetes Care. 2004;27:1915-1921.

Lifestyle Management for Type 2 Diabetes. Are Family Physicians Ready and Willing?
Harris SB, Petrella RJ, Lambert-Lanning A, Leadbetter W, Cranston L. Can Fam Physician. 2004;50:1235-1243.

Beneficial Effect of Nateglinide on Insulin Resistance in Type 2 Diabetes
Hazama Y, Matsuhisa M, Ohtoshi K, et al. Diabetes Res Clin Pract. 2006;71:251-255.

Prevalence of Overweight and Obesity Among US Children, Adolescents, and Adults, 1999–2002
Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. JAMA. 2004;291:2847-2850.

Exenatide Versus Insulin Glargine in Patients With Suboptimally Controlled Type 2 Diabetes: A Randomized Trial
Heine RJ, Van Gaal LF, Johns D Mihm MJ, Widel MH, Brodows RG, for the GWAA Study Group. Ann Int Med. 2005;143:559-570.

Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes
Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, Draeger E. Diabetes. 2004;53:1614-1620.

Hypoglycaemia with Insulin Aspart: a Double-blind, Randomised, Crossover Trial in Subjects with Type 1 Diabetes
Heller SR, Colagiuri S, Vaaler S, Wolffenbuttel BH, Koelendorf K, Friberg HH, Windfeld K, Lindholm A. Diabet Med. 2004;21:769-775.

Prevalence, Care, and Outcomes for Patients with Diet-Controlled Diabetes in General Practice: Cross-Sectional Survey
Hippisley-Cox J, Pringle M. Lancet. 2004;363:423-428.

Glycemic Index and Dietary Fiber and the Risk of Type 2 Diabetes
Hodge AM, English DR, O’Dea K, Giles GG. Diabetes Care. 2004;27:2701-2706.

Premature Birth and Later Insulin Resistance
Hofman PL, Regan F, Jackson WE, Jefferies C, Knight DB, Robinson EM, Cutfield WS. N Engl J Med. 2004;351:2179-2186.

Efficacy and Safety of Inhaled Insulin (Exubera) Compared With Subcutaneous Insulin Therapy in Patients With Type 2 Diabetes: Results of a 6-Month, Randomized, Comparative Trial
Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, Levin SR. Diabetes Care. 2004;27:2356-2362.

Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman RR, Thorne KI, Farmer AJ, et al; 4-T Study Group. N Engl J Med. 2007;357:1716-1730.

Visfatin: A New Adipokine
Hug C, Lodish HF. Sciencexpress 2004. Published online 16 Dec 2004.

Stem-cell Therapy for Diabetes Mellitus
Hussain MA, Theise ND. Lancet. 2004;364:203-205.

Increased Carotid Intima-Media Thickness and Stiffness in Obese Children
Iannuzzi A, Licenziati MR, Acampora C, Salvatore V, Auriemma L, Romano ML, Panico S, Rubba P, Trevisan M. Diabetes Care. 2004;27:2506-2508.

Thirty-Year Trends in Cardiovascular Risk Factor Levels Among US Adults With Diabetes: National Health and Nutrition Examination Surveys, 1971–2000
Imperatore G, Cadwell BL, Geiss L, Saadinne JB, Williams DE, Ford ES, Thompson TJ, Venkat Narayan KM, Gregg EW. Am J Epidemiol. 2004;160:531-553.

Incretins, Insulin Secretion, and Type 2 Diabetes Mellitus
Vilsbøll T, Holst JJ. Diabetologia. 2004;47:357-366.

Insulin Analogues (Insulin Detemir and Insulin Aspart) Versus Traditional Human Insulins (NPH Insulin and Regular Human Insulin) in Basal-bolus Therapy for Patients With Type 1 Diabetes
Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Diabetologia. 2004;47:622-629.

Role of Proinflammatory Cytokines in the Cause of Neuropathic Osteoarthropathy (Acute Charcot Foot) in Diabetes
Jeffcoate W. Lancet. 2005;366:2058-2061.

Who is Tested for Diabetic Kidney Disease and Who Initiates Treatment?
The Translating Research in Action for Diabetes (TRIAD) Study

Who is Tested for Diabetic Kidney Disease and Who Initiates Treatment? The Translating Research in Action for Diabetes (TRIAD) Study
Johnson SL, Tierney EF, Onyemere KU, et al. Diabetes Care. 2006;29:1733-1738.

Intravitreal Triamcinolone Acetonide: A Change in a Paradigm
Jonas JB. Ophthalmic Res. 2006;38:218-245.

Gender Difference in the Impact of Type 2 Diabetes on Coronary Heart Disease Risk
Juutilainen A, Kortelainen S, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Diabetes Care. 2004;27:2898-2904.

Type 2 Diabetes as a Coronary Heart Disease Equivalent: An 18-year Prospective Population-based Study in Finnish Subjects
Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laasko M. Diabetes Care. 2005;28:2901-2907.

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. N Engl J Med. 2006;355:2427-2443.

Walking Performance in People with Diabetic Neuropathy: Benefits and Threats
Kanade RV, van Deursen RWM, Harding K, Price P. Diabetologia. 2006;49:1747-1754.

Intrasubject Variability of Inhaled Insulin in Type 1 Diabetes: a Comparison With Subcutaneous Insulin
Kapitza C, Hompesch M, Scharling B, Heise T. Diabetes Technol Ther. 2004;6:466-472.

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients with Type 2 Diabetes Treated With Metformin and a Sulfonylurea
Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Diabetes Care. 2005;28:1083-1091.

Diabetes Care Quality in the Veterans Affairs Health Care System and Commercial Managed Care: the TRIAD Study
Kerr EA, Gerzoff RB, Krein SL, Selby JV, Piette JD, Curb JD, Herman WH, Marrero DG, Narayan KM, Safford MM, Thompson T, Mangione CM. Ann Intern Med. 2004;141:272-281.

Clinical Observations of Exenatide Treatment
King AB, Wolfe G, Healy S. Diabetes Care. 2006;29:1984.

Retinal Vascular Caliber in Person with Type 2 Diabetes
The Wisconsin Epidemiological Study of Diabetic Retinopathy: XX

The Relation of Ambulatory Blood Pressure and Pulse Rate to Retinopathy in Type 1 Diabetes Mellitus: the Renin-Angiotensin System Study
Klein R, Moss SE, Sinaiko AR, Zinman B, Gardiner R, Suissa S, Donnelly SM, Kramer MS, Goodyer P, Strand T, Mauer M. Ophthalmology. 2006;113:2231-2236. Epub 2006 Sep 25.

Metabolic Control of Diabetes Is Associated With an Improved Response of Diabetic Retinopathy to Panretinal Photocoagulation
Kotoula MG, Koukoulis GN, Zintaras E, Karabatsas CH, Chatzoulis DZ. Diabetes Care. 2005;28:2454-2457.

Screening for Kidney Disease in Adults With Diabetes and Prediabetes
Kramer H. Curr Opin Nephrol Hypertens. 2005;14:249-252.

Medication Adherence and Associated Hemoglobin A1C in Type 2 Diabetes
Krapek K, King K, Warren SS, George KG, Caputo DA, Mihelich K, Holst EM, Nichol MB, Shi SG, Livengood KB, Walden S, Lubowski TJ. Ann Pharmacother. 2004;38:1357-1362.

Lipids and Lipoproteins in Patients with Type 2 Diabetes
Krauss RM. Diabetes Care. 2004;27:1496-1504.

Interleukin-1-Receptor Antagonist in Type 2 Diabetes Mellitus
Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. N Engl J Med. 2007;356:1517-1526.

Risk Factors for Foot Infections in Individuals With Diabetes
Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Diabetes Care. 2006;29:1288-1293.

Medication Adherence and the Associated Health-Economic Impact Among Patients With Type 2 Diabetes Mellitus Converting to Insulin Pen Therapy: an Analysis of Third-Party Managed Care Claims Data
Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Clin Ther. 2006;28:1712-1725.

Urinary Albumin Excretion Rate Is Associated With Increased Ambulatory Blood Pressure in Normoalbuminuric Type 2 Diabetic Patients
Leitao CB, Canani LH, Polson PB, Molon MP, Pinotti AF, Gross JL. Diabetes Care. 2005;28:1724-1729.

Postprandial Glucose Regulation: New Data and New Implications
Leiter LA, Ceriello A, Davidson JA, et al. Clin Ther. 2005;27(suppl B):S42-S56.

Induction of Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients Is Associated With Improvement of Beta-cell Function
Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J. Diabetes Care. 2004;27:2597-2602.

Relationship of Depression and Diabetes Self-Care, Medication Adherence, and Preventive Care
Lin EH, Katon W, Von Korff M, Rutter C, Simon GE, Oliver M, Ciechanowski P, Ludman EJ, Bush T, Young B. Diabetes Care. 2004;27:2154-2160.

Exenatide: Effect of Injection Time on Postprandial Glucose in Patients With Type 2 Diabetes
Linnebjerg H, Kotharet PA, Skrivanek Z, et al. Diabetic Med. 2006;23:240-245.

The Lipid Triad in Type 2 Diabetes Prevalence and Relevance of Hypertriglyceridemia or Low High Density Lipoprotein Syndrome in Type 2 Diabetes
Temelkova-Kurktschiev T, Hanefeld M. Exp Clin Endocrinol Diabetes. 2004;112:75-79.

Screening for Retinopathy in the Pediatric Patient With Type 1 Diabetes Mellitus
Lueder GT, Silverstein J. Pediatrics. 2005;116:270-273.

Hypertension Prevalence, Awareness, Treatment, and Control in an Adult Type 1 Diabetes Population and a Comparable General Population
Maahs D, Kinney L, Wadwa P, et al. Diabetes Care. 2005;28:301-306.

Higher Prevalence of Elevated Albumin Excretion in Youth With Type 2 Than Type 1 Diabetes: The SEARCH for Diabetes in Youth Study
Maahs DM, Snively BM, Bell RA, et al. Diabetes Care. 2007 Jul 13; [Epub ahead of print]

Improved Glycemic Control with No Weight Increase in Patients with Type 2 Diabetes After Once-daily Treatment with the Long-acting Glucagon-like Peptide 1 Analog Liraglutide (NN2211): A 12-week, Double-blind, Randomized, Controlled Trial.
Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group. Diabetes Care. 2004;27:1335-1342.

Impact of the Metabolic Syndrome on Mortality from Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults
Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, Williams GR. Circulation. 2004;110:1245-1250.

Inflammatory Markers and Risk of Developing Type 2 Diabetes in Women
Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Diabetes. 2004;53:693-700.

Neuropathy Among the Diabetes Control and Complications Trial Cohort 8 Years After Trial Completion
Martin CL, Albers J, Herman WH, et al. Diabetes Care. 2006;29:340-344.

Glomerular Filtration Rate Changes in Normoalbuminuric and Microalbuminuric Type 2 Diabetic Patients and Normal Individuals. A 10-year Follow-up
Marussi M, Gross JL, Silveiro SP. Journal of Diabetes and its Complications. 2006;20:210-215.

Glomerular Filtration Rate Changes in Normoalbuminuric and Microalbuminuric Type 2 Diabetic Patients and Normal Individuals. A 10-year Follow-up
Marussi M, Gross JL, Silveiro SP. J Diabetes Complications. 2006;20:210-215.

Specialist Nurse-Led Clinics to Improve Control of Hypertension and Hyperlipidemia in Diabetes: Economic Analysis of the SPLINT Trial
Mason JM, Freemantle N, Gibson JM, New JP. Diabetes Care. 2005;28:40-46.

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
Matikainen N, Mänttäri S, Schweizer A, et al. Diabetologia. 2006;49:2049-2057.

Relationship between the ability to recognize energy intake and expenditure, and blood sugar control in type 2 diabetes mellitus patients
Matsushita Y, Yokoyama T, Homma T, Tanaka H, Kawahara K. Diabet Res Clin Pract. 2005;67:220-226.

Long-term Therapy with Addition of Pioglitazone to Metformin Compared with the Addition of Gliclazide to Metformin in Patients with Type 2 Diabetes: A Randomized, Comparative Study
Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Diabetes Metab Res Rev. Published online June 15, 2004.

Differences in Diabetes Prevalence, Incidence, and Mortality Among the Elderly of Four Racial/Ethnic Groups: Whites, Blacks, Hispanics, and Asians
McBean AM, Li S, Gilbertson DT, Collins AJ. Diabetes Care. 2004;27:2317-2324.

Biological Variation in HbA1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes
McCarter RJ, Hempe JM, Gomez R, Chalew SA. Diabetes Care. 2004;27:1259-1264.

The Development of a New Measure of Quality of Life for Young People with Diabetes Mellitus: the ADDQoL-Teen
McMillan CV, Honeyford RJ, Datta J, Madge NJ, Bradley C. Health Qual Life Outcomes. 2004;2:61. Epub Nov 2004.

Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels
Melander A, Folino-Gallo P, Walley T, et al. Diabetologia. 2006;49:2024-2029.

Insulin Detemir Improves Glycemic Control With Less Hypoglycemia and No Weight Gain in Patients With Type 2 Diabetes Who Were Insulin Naive or Treated With NPH or Insulin Glargine: Clinical Practice Experience From a German Subgroup of the PREDICTIVE Study
Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Diabetes Obes Metab. 2007;9:418-427.

The Metabolic Syndrome, Circulating Oxidized LDL, and Risk of Myocardial Infarction in Well-Functioning Elderly People in the Health, Aging, and Body Composition Cohort
Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, Goodpaster B, Harris TB. Diabetes. 2004;53:1068-1073.

A Comparison of the Monofilament With Other Testing Modalities for Foot Ulcer Susceptibility
Miranda-Palma B, Sosenko JM, Bowker JH, Mizel MS, Boulton AJM. Diabetes Res Clin Pract. 2005;70:8-12.

Evaluating Adjunctive Surgical Procedures during Vitrectomy for Diabetic Macular Edema
Mochizuki Y, Hata Y, Enaida H, et al. Retina. 2006;26:143-148.

Adiponectin and Leptin Concentrations May Aid in Discriminating Disease Forms in Children and Adolescents With Type 1 and Type 2 Diabetes
Morales A, Wasserfall C, Brusko T, Carter C, Schatz D, Silverstein J, Ellis T, Atkinson M. Diabetes Care. 2004;27:2010-2014.

“Pressure Gradient” as an Indicator of Plantar Skin Injury
Mueller MJ, Zou D, Lott DJ. Diabetes Care. 2005;28:2908-2912.

Effect of Pioglitazone on Carotid Intima-Media Thickness and Arterial Stiffness in Type 2 Diabetic Nephropathy Patients
Nakamura T, Matsuda T, Kawagoe Y, Ogawa H, Takahashi Y, Sekizuka K, Koide H. Metabolism. 2004;53:1382-1386.

A Comparison of Twice-daily Exenatide and Biphasic Insulin Aspart in Patients With Type 2 Diabetes Who Were Suboptimally Controlled With Sulfonylurea and Metformin: A Non-inferiority Study
Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M. Diabetologia. 2007;50:259-267.

Sex-associated Differences in Clinical Outcomes After Coronary Stenting in Patients with Diabetes Mellitus
Ndrepepa G, Mehilli J, Bollwein H, Pache J, Schomig A, Kastrati A. Am J Med. 2004;117:830-836.

Self-management Interventions for Chronic Illness
Newman S, Steed L, Mulligan K. Lancet. 2004;364:1523–1537.

Treatment Escalation and Rise in HbA1c Following Successful Initial Metformin Therapy
Nichols G, Alexander C, Girman C, Kamal-Bahl S, Brown J. Diabetes Care. 2006;29:504-509.

Strategic Plan for NIH Obesity Research
National Institutes of Health (NIH) Obesity Research Task Force. Bethesda, MD: US Department of Health and Human Services; 2004. NIH Publication No. 04-5493.

Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Nissen SE, Wolski K, Topol EJ. JAMA. Published online October 20, 2005.

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death From Cardiovascular Causes
Nissen SE, Wolski K. N Engl J Med. 2007;356:2457-2471.

Effects of Glucagon-Like Peptide-1 on Endothelial Function in Type 2 Diabetes Patients With Stable Coronary Artery Disease
Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, Sjoholm A. Am J Physiol Endocrinol Metab. 2004;287:E1209-E1215.

Regression of Iris Neovascularization After Intravitreal Injection of Bevacizumab in Patients with Proliferative Diabetic Retinopathy
Oshima Y, Sakaguchi S, Gomi F, Tano Y. Am J Opthalmol. 2006;142:155-157.

Effect of Rosiglitazone Versus Insulin on the Pancreatic Beta-Cell Function of Subjects With Type 2 Diabetes
Ovalle F, Bell DS. Diabetes Care. 2004;27:2585-2589.

Antihypertensive Therapy and Incidence of Type 2 Diabetes in an Elderly Cohort
Padwal R, Mamdani M, Alter DA, Hux JE, Rothwell DM, Tu K, Laupacis A. Diabetes Care. 2004;27:2458-2463.

Association of Protein Tyrosine Phosphatase 1B Gene Polymorphisms With Measures of Glucose Homeostasis in Hispanic Americans: The Insulin Resistance Atherosclerosis Study (IRAS) Family Study
Palmer ND, Bento JL, Mychaleckyj JC, Langefeld CD, Campbell JK, Norris JM, Haffner SM, Bergman RN, Bowden DW. Diabetes. 2004;53:3013-3019.

The 30-Year Natural History of Type 1 Diabetes Complications: The Pittsburgh Epidemiology of Diabetes Complications Study Experience
Pambianco G, Costacou T, Ellis D, Becker D, Klein R, Orchard T. Diabetes. 2006;55:1463-1469.

The 30-Year Natural History of Type 1 Diabetes Complications: The Pittsburgh Epidemiology of Diabetes Complications Study Experience
Pambianco G, Costacou T, Ellis D, Becker D, Klein R, Orchard T. Diabetes. 2006;55:1463-1469.

The sequential changes in the fasting plasma glucose levels within normoglycemic range predict type 2 diabetes in healthy, young men
Park Y-W, Chang Y, Sung KC, Ryu S, Sung E, Kim WS. Diabetes Res Clin Pract. 2006;73:329-335.

Vitreous and Aqueous Concentration of Proangiogenic, Antiangiogenic Factors and Other Cytokines in Diabetic Retinopathy Patients With Macular Edema: Implications for Structural Differences in Macular Profiles
Patel J, Tombran-Tink J, Hykin P, Gregor Z, Cree I. Experimental Eye Research. 2006;82:798-806.

Diabetic Cataract Removal: Postoperative Progression of Maculopathy—Growth Factor and Clinical Analysis
Patel JI, Hyken PG, Cree IA. Br J Opthalmol. 2006;90:697-701.

Effects of Dietary Glycaemic Index on Adiposity, Glucose Homeostasis, and Plasma Lipids in Animals
Pawlak DB, Kushner JA, Ludwig DS. Lancet. 2004;364:778-785.

Aspirin Use Among Adults with Diabetes: Recent Trends and Emerging Sex Disparities
Persell SD, Baker DW. Arch Intern Med. 2004;164:2492-2499.

Decreasing the Risk of Diabetic Retinopathy in a Study of Case Management: The California Medi-Cal Type 2 Diabetes Study
Pettitt DJ, Wollitzer AO, Jovanovic L, He G. Diabetes Care. 2005;28:2819-2822.

Resistance to Insulin Therapy Among Patients and Providers: Results of the Cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) Study
Peyrot M, Rubin RR, Lauritzen T, et al. Diabetes Care. 2005;28:2673-2679.

Pioglitazone as Monotherapy or in Combination With Sulfonylurea or Metformin Enhances Insulin Sensitivity in Patients With Type 2 Diabetes
Tan MH, Glazer NB, Johns D, Widel M, Gilmore KJ. Curr Med Res Opin. 2004;20:723-728.

The Effect of Ruboxistaurin on Visual Loss in Patients With Moderately Severe to Very Severe Nonproliferative Diabetic Retinopathy: Initial Results of the Protein Kinase C β Inhibitor Diabetic Retinopathy Study (PKC-DRS) Multicenter Randomized Trial
The PKC-DRS Study Group. Diabetes. 2005;54:2188-2197.

Effect of Ruboxistaurin on Visual Loss in Patients with Diabetic Retinopathy
PKC-DRS2 Group. Ophthalmology. 2006. Epub ahead of print.

What’s So Tough About Taking Insulin? Addressing the Problem of Psychological Insulin Resistance in Type 2 Diabetes
Polonsky WH, Jackson RA. Clin Diabetes. 2004;22:147-150.

Laparoscopic Gastric Banding Prevents Type 2 Diabetes and Arterial Hypertension and Induces Their Remission in Morbid Obesity: A 4-year Case-controlled Study
Pontiroli AE, Folli F, Paganelli M, et al. Diabetes Care. 2005;28:2703-2709.

Better Long-term Glycemic Control With the Basal Insulin Glargine as Compared With NPH in Patients With Type 1 Diabetes Mellitus Given Meal-time Lispro Insulin
Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Perriello G, Bolli GB. Diabet Med. 2004;21:1213-1220.

Renal Hyperfiltration in Type 2 Diabetes: Effect of Age-related Decline in Glomerular Filtration Rate
Premaratne E, Macisaac RJ, Tsalamandris C, Panagiotopoulos S, Smith T, Jerums G. Diabetologia. 2005;48:2486-2493.

Rosiglitazone and Cardiovascular Risk
Psaty BM, Furberg CD. N Engl J Med. 2007;356:2522-2524.

Comparison of Different Definitions of the Metabolic Syndrome in Relation to Cardiovascular Mortality in European Men and Women
The DECODE Study Group; Qiao Q. Diabetologia. 2006;49:2837-2846.

Initiating Insulin Therapy in Type 2 Diabetes
Raskin P, Allen E, Hollander P, et al. Diabetes Care. 2005;28:260-265.

Insulin Detemir and Insulin Aspart: A Promising Basal-Bolus Regimen for Type 2 Diabetes
Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Diabetes Res Clin Pract. 2004;66:193-201.

Long-Term Effects of Exenatide Therapy Over 82 Weeks on Glycaemic Control and Weight in Over-Weight Metformin-Treated Patients With Type 2 Diabetes Mellitus
Ratner RE, Maggs D, Nielson LL, et al. Diabetes Obes Metab. 2006;8:419-428.

Dose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin Lispro
Rave KM, Nosek L, de la Pena A, et al. Diabetes Care. 2005;28:2400-2405.

Are We Underestimating Diabetes-Related Lower-Extremity Amputation Rates? Results and Benefits of the First Prospective Study
Rayman G, Krishnan ST, Baker NR, Wareham AM, Rayman A. Diabetes Care. 2004;27:1892-1896.

Efficacy and Safety of the Dipeptidyl Peptidase-IV Inhibitor Sitagliptin as Monotherapy in Patients With Type 2 Diabetes
Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman E, Khatami H, and the Sitagliptin Study 023 Group. Diabetologia. 2006;49:2564-2571.

Two-year Outcome of a Combination of Weight Loss Therapies for Type 2 Diabetes
Redmon JB, Reck KP, Raatz SK, et al. Diabetes Care. 2005;28:1311-1315.

Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections: The Impact of Baseline A1C
Retnakaran R, Hochman J, Devries JH, Hanaire-Broutin H, Heine RJ, Melki V, Zinman B. Diabetes Care. 2004;27:2590-2596.

Effect of Calcium Dobesilate on Progression of Early Diabetic Retinopathy: A Randomised Double-blind Study
Ribeiro ML, Seres AI, Carneiro AM, et al; DX-Retinopathy Study Group. Graefe’s Arch Clin Exp Ophthalmol. 2006;DOI 10.1007/s00417-006-0318-2.

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Pioglitazone Therapy in Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Clin Ther. 2006;28:1556-1568.

Triple Therapy in Type 2 Diabetes: Insulin Glargine or Rosiglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin in Insulin-naïve Patients
Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G; on Behalf of the Insulin Glargine 4014 Study Investigators. Diabetes Care. 2006;29:554-559.

Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes: A 24-Week, Double-blind, Randomized Trial
Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Diabetes Care. 2007;30:217-223.

Influence of Patient Literacy on the Effectiveness of a Primary Care-based Diabetes Disease Management Program
Rothman RL, DeWalt DA, Malone R, Bryant B, Shintani A, Crigler B, Weinberger M, Pignone M. JAMA. 2004;292:1711-1716.

Preventing Microalbuminuria in Type 2 Diabetes
Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. N Engl J Med. 2004;351:1941-1951.

Ragaglitazar Improves Glycemic Control and Lipid Profile in Type 2 Diabetic Subjects: A 12-week, Double-blind, Placebo-controlled Dose-ranging Study with an Open Pioglitazone Arm
Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, Nunez M, Reinhardt RR; Ragaglitazar Dose-Ranging Study Group. Diabetes Care. 2004;27:1324-1329.

Metformin Monotherapy for Type 2 Diabetes Mellitus
Saenz A, Fernandez-Esteban I, Matrix A, Ausejo M, Roque M, Moher D. Cochrane Database Syst Rev. 2005;(3):CD002966. DOI: 10.1002/14561858.CD002966.

Oral Sildenafil in the Treatment of Erectile Dysfunction in Diabetic Men: a Randomized Double-blind and Placebo-controlled Study
Safarinejad MR. J Diabetes Complications. 2004;18:205-210.

Anthropometric Parameters in Infants of Gestational Diabetic Women With Strict Glycemic Control
Salim R, Hasanein J, Nachum Z, Shalev E. Obstet Gynecol. 2004;104:1021-1024.

Reduction in Estimated Risk for Coronary Artery Disease After Use of Ezetimibe With a Statin
Sampalis JS, Bissonnette S, Habib R, Boukas S; Ezetrol Add-On Investigators. Ann Pharmacother. 2007;41:1345-1351.

Severe Hypo-alpha-lipoproteinemia During Treatment with Rosiglitazone
Sarker A, Semple RK, Dinneen SF, O’Rahilly S, Martin SC. Diabetes Care. 2004;27:2577-2580.

Cardiovascular Risk Factors and Disease Management in Type 2 Diabetic Patients with Diabetic Nephropathy
Sasso FC, DeNicola L, Nasti R, et al, for the NID-2 (Nephropathy in Diabetes-Type 2) Study Group. Diabetes Care. 2006;29:498-503.

Review of the Performance of Methods to Identify Diabetes Cases Among Vital Statistics, Administrative, and Survey Data
Saydah SH, Geiss LS, Tierney E, Benjamin SM, Engelgau M, Brancati F. Ann Epidemiol. 2004;14:507-516.

Amylin Agonists: A Novel Approach in the Treatment of Diabetes
Schmitz O, Brock B, Rungby J. Diabetes. 2004;53(suppl 3):S233-S238.

Atorvastatin Improves Diabetic Dyslipidemia and Increases Lipoprotein Lipase Activity In Vivo
Schneider JG, von Eynatten M, Parhofer KG, Volkmer JE, Schiekofer S, Hamann A, Nawroth PP, Dugi KA. Atherosclerosis. 2004;175:325-331.

Modulation of Food Intake by Glucose in Patients With Type 2 Diabetes
Schultes B, Peters A, Hallschmid M, et al. Diabetes Care. 2005;28:2884-2889.

Sugar-Sweetened Beverages, Weight Gain, and Incidence of Type 2 Diabetes in Young and Middle-Aged Women
Schulze MB, Manson JE, Ludwig DS, Colditz GA, Stampfer MJ, Willett WC, Hu FB. JAMA. 2004;292:927-934.

Primary Prevention of Diabetes: What Can Be Done and How Much Can Be Prevented?
Schulze MB, Hu FB. Annu Rev Public Health. 2004. Epub Oct 26 2004.

Meta-analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus
Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Ann Intern Med. 2004;141:421-431.

The Impact of Smoking and Quitting Smoking on Patients With Diabetes
The Impact of Smoking and Quitting Smoking on Patients With Diabetes Sherman, JJ. Diabetes Spectrum. 2005;18:202-208.

Short Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes
Ryan EA, Imes S, Wallace C. Diabetes Care. 2004;27:1028-1032.

Physical Activity/Exercise and Type 2 Diabetes: A Consensus Statement From the American Diabetes Association
Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C, White RD. Diabetes Care. 2006;29:1433-1438.

Dose-response Relation Between Sulfonylurea Drugs and Mortality in Type 2 Diabetes Mellitus: a Population-based Cohort Study
Simpson S, Majumdar SR, Tsyyuki R, Eurich D, Johnson J. CMAJ. 2006;174:169-174.

Effects of Glycemic Control on Diabetes Complications and on the Prevention of Diabetes
Skyler JS. Clin Diabetes. 2004;22:162-166.

Effects of Pioglitazone on Endothelial Function, Insulin Sensitivity, and Glucose Control in Subjects With Coronary Artery Disease and New-Onset Type 2 Diabetes.
Sourij H, Zweiker R, Wascher T. Diabetes Care. 2006;29:1039-1045.

Intravitreal Bevacizumab (Avastin) Treatment of Proliferative Diabetic Retinopathy Complicated by Vitreous Hemorrhage
Spaide RF, Fisher YL. Retina. 2006;26:275-278.

Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75)
Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Diabetologia. 2006;49:1761-1769.

Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists on Mortality and Renal Outcomes in Diabetic Nephropathy: Systematic Review
Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. BMJ. 2004;329:828. Epub 2004 Sep 30.

Improved Glycemic Control Without Weight Gain Using Triple Therapy in Type 2 Diabetes
Strowig SM, Aviles-Santa ML, Raskin P. Diabetes Care. 2004;27:1577-1583.

Socioeconomic Status, Cardiovascular Risk Factors and the Incidence of Microvascular and Macrovascular Disease in Type 1 Diabetes
Swaminathan K, Lewis S, Morris AD on behalf of the Royal College of Physicians of Edinburgh Diabetic Registry Group. Br J Diabetes Vasc Dis. 2004;4:180-188.

Mortality of South Asian Patients with Insulin-Treated Diabetes Mellitus in the United Kingdom: A Cohort Study
Swerdlow AJ, Laing SP, Dos Santos Silva I, Slater SD, Burden AC, Botha JL, Waugh NR, Morris AD, Gatling W, Bingley PJ, Patterson CC, Qiao Z, Keen H. Diabet Med. 2004;21:845-851.

Lowering the Criterion for Impaired Fasting Glucose: Impact on Disease Prevalence and Associated Risk of Diabetes and Ischemic Heart Disease
Tai ES, Goh SY, Lee JJ, Wong MS, Heng D, Hughes K, Chew SK, Cutter J, Chew W, Gu K, Chia KS, Tan CE. Diabetes Care. 2004;27:1728-1734.

Distinct Diagnostic Criteria of Fulminant Type 1 Diabetes Based on Serum C-Peptide Response and HbA1c Levels at Onset
Tanaka S, Endo T, Aida K, Shimura H, Yokomori N, Kaneshige M, Furuya F, Amemiya S, Mochizuki M, Nakanishi K, Kobayashi T. Diabetes Care. 2004;27:1936-1941.

Divergent Regulation of Hepatic Glucose and Lipid Metabolism by Phosphoinositide 3-kinase via Akt and PKC λ/ζ
Taniguchi CM, Kondo T, Sajan M, et al. Cell Metabolism. 2006;3:343-353.

Diagnostic Thresholds for Diabetes: The Association of Retinopathy and Albuminuria with Glycaemia
Tapp RJ, Zimmet PZ, Harper CA, et al. Diabetes Res Clin Pract. 2006;73:315-321.

Vascular Risk Factors and Diabetic Neuropathy
Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH; EURODIAB Prospective Complications Study Group. N Engl J Med. 2005;352:342-350.

Vascular Risk Factors and Diabetic Neuropathy
Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH; EURODIAB Prospective Complications Study Group. N Engl J Med. 2005;352:342-350.

Serum Lipids and the Progression of Nephropathy in Type 1 Diabetes
Thomas MC, Rosengard-Barlund M, Mills V, et al. Diabetes Care. 2006;29:317-322.

Exercise for Type 2 Diabetes Mellitus
Thomas DE, Elliot EJ, Naughton GA. Cochrane Database Syst Rev. 2006;3:1-103.

Metabolic Syndrome in Type 1 Diabetes: Association With Diabetic Nephropathy and Glycemic Control (The FinnDiane Study)
Thorn L, Forsblom C, Fagerudd J, et al. Diabetes Care. 2005;28:2019-2024.

Validation of a System of Foot Ulcer Classification in Diabetes Mellitus
Treece KA, Macfarlane RM, Pound N, Game FL, Jeffcoate WJ. Diabet Med. 2004;21:987-991.

Interaction of Tumor Necrosis Factor alpha and Thiazolidinedione Regulated Pathways in Obesity
Wellen KE, Uysal KT, Wiesbrock S, Yang Q, Chen H, Hotamisligil GS. Endocrinology. 2004;145:2214-2220.

The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes
Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. Diabetes Care. 2005;28:2686-2690.

Risks of Progression of Retinopathy and Vision Loss Related to Tight Blood Pressure Control in Type 2 Diabetes Mellitus: UKPDS 69
UKPDS Group. Arch Ophthalmol. 2004;122:1631-1640.

Treatment of Diabetic Ketoacidosis With Subcutaneous Insulin Aspart
Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Diabetes Care. 2004;27:1873-1878.

Is Depression Related to Subsequent Diabetes Mellitus?
van den Akker M, Schuurman A, Metsemakers J, Buntinx F. Acta Psychiatrica Scandinavica. 2004;110:178-183.

Diabetic Patients Without Vascular Complications Display Enhanced Basal Platelet Activation and Decreased Antioxidant Status
Véricel E, Januel C, Carreras M, Moulin P, Lagarde M. Diabetes. 2004;53:1046-1051.

Liraglutide, a Long-acting Human Glucagon-like Peptide-1 Analog Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes
Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, Verhoeven R, Buganova I, Madsbad S. Diabetes Care. 2007;30:1608-1610.

Exenatide Therapy in Obese Patients With Type 2 Diabetes Mellitus Treated With Insulin
Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Endocr Pract. 2007;13:444-450.

Beta-cell Dysfunction in Patients With Acute Myocardial Infarction but Without Previously Known Type 2 Diabetes: A Report From the GAMI Study
Wallander M, Bartnik M, Efendic S, Hamsten A, et al. Diabetologia. Epub ahead of print. September, 2005.

Relationship of Physical Activity vs Body Mass Index with Type 2 Diabetes in Women
Weinstein AR, Sesso HD, Lee IM, Cook NR, Manson JE, Buring JE, Gaziano JM. JAMA. 2004;292:1188-1194.

Persistence of Benefits of Continuous Subcutaneous Insulin Infusion in Very Young Children with Type 1 Diabetes: A Follow-up Report
Weinzimer SA, Ahern JH, Doyle EA, Vincent MR, Dziura J, Steffen AT, Tamborlane WV. Pediatrics. 2004;114:1601-1605.

Impact of Fasting and Postprandial Glycemia on Overall Glycemic Control in Type 2 Diabetes: Importance of Postprandial Glycemia to Achieve Target Hba1c Levels
Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, Gerich JE, Goke B. Diabetes Res Clin Pract. 2007;77:280-285.

Translating Lifestyle Intervention to Practice in Obese Patients with Type 2 Diabetes: Improving Control with Activity and Nutrition (ICAN) Study
Wolf AM, Conaway MR, Crowther JQ, Hazen KY, Nadler JL, Oneida B, Bovbjerg VE. Diabetes Care. 2004;27:1570-1576.

Defining and Reporting Hypoglycemia in Diabetes: A Report from the American Diabetes Association Workgroup on Hypoglycemia
American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28:1245-1249.

Diabetes Mellitus and Risk of Dementia in the Kungsholmen Project: a 6-year Follow-up Study
Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Neurology. 2004;63:1181-1186.

Diabetes, Impaired Fasting Glucose, and Development of Cognitive Impairment in Older Women
Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Neurology. 2004;63:658-663.

The Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline
Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB. JAMA. 2004;292:2237-2242.

Insulin Therapy and Colorectal Cancer Risk Among Type 2 Diabetes Mellitus Patients
Yang YX, Hennessy S, Lewis JD. Gastroenterology. 2004;127:1044-1050.

Thiazolidinediones
Yki-Jarvinen H. N Engl J Med. 2004;351:1106-1118.

Additive Effects of Glucagon-Like Peptide 1 and Pioglitazone in Patients with Type 2 Diabetes
Zander M, Christiansen A, Madsbad S, Juul Holst J. Diabetes Care. 2004;27:1910-1914.

Panretinal Photocoagulation and Intravitreal Triamcinolone Acetonide for the Management of Proliferative Diabetic Retinopathy With Macular Edema
Zein W, Noureddin BN, Jurdi FA, Schakal A, Bashshur ZF. Retina. 2006;26:137-142.

Upper Gastrointestinal Sensory-motor Dysfunction in Diabetes Mellitus
Zhao J, Frojkaer J, Drewes A, Ejskjaer N. World J Gastroenterol. 2006;12:2846-2857.

Results of the Glucose-Lowering Effect of Welchol Study (GLOWS): a Randomized, Double-Blind, Placebo-Controlled Pilot Study Evaluating the Effect of Colesevelam Hydrochloride on Glycemic Control in Subjects With Type 2 Diabetes
Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Clin Ther. 2007;29:74-83.